Thursday 7 March 2013
Opening remarks & Positioning the EORTC in the changing clinical research landscape – R. Stupp
SPECTAcolor, an EORTC initiative – S. Tejpar
OncoTrack: Precision medicine for colon cancer driven by genomics and systems biology – D. Henderson
The EORTC brain metastasis platform – W. Wick and M. Preusser
Emerging opportunities for drug development with radiation oncology – V. Grégoire
Integration of pharmacogenomics in clinical research – U. McDermott (Sanger Institute)
Friday 8 March 2013
New challenges for industry and new approaches to partnerships between industry and EORTC – M. Chlebus (EFPIA)
The changing landscape of drug development – S. Arlington (PwC)
Role of academia in the changing landscape: the regulator’s point of view – F. Pignatti (EMA)
Long term follow up studies : the Children’s Leukemia Group experience – C. Piette